Humoral and Cellular Immune Responses After Influenza Vaccination in Patients With Postcancer Fatigue and in Patients With Chronic Fatigue Syndrome
NCT ID: NCT01651754
Last Updated: 2012-07-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
72 participants
INTERVENTIONAL
2010-09-30
2012-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PCF (n=20) and CFS patients (n=20) will be vaccinated against influenza. Age and gender matched non-fatigued cancer survivors (n=20) and healthy controls (n=20) will be included for comparison. Antibody responses will be measured at baseline and at day 21 by a hemagglutination inhibition test. T cell responses will be measured at baseline and at day 7 by lymphocyte proliferation, activation, and cytokine secretion.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Hypotheses about mechanisms explaining cancer-related fatigue have already been described, including dysregulation of brain serotonin, dysregulation of the hypothalamic-pituitary-adrenal axis responsiveness, disruption of the circadian rhythm, alterations in muscle and ATP metabolism, and activation of the vagal afferent nerve. Furthermore, the presence of an underlying immunological problem has been suggested as an explanation for PCF.
Another group of patients suffering from severe fatigue symptoms are patients with CFS. The estimated worldwide prevalence of CFS is 0.4-1%. In the Netherlands, about 100.000 patients are suffering from chronic fatigue, of which 30.000 to 40.000 suffer from CFS. In contrast to fatigue in patients with PCF, in patients with CFS no clear precipitating factor could be identified. Also for patients with CFS, a cognitive behavior therapy is designed, which is proven to be effective, but the pathophysiological mechanism of CFS remains unclear.
Hypotheses explaining the pathophysiological mechanism of CFS include morphological and metabolic alterations in the brain, diminished central activation of muscles, altered central nervous system functioning, a neuroendocrine disturbance, or cognitive impairment. Furthermore, the presence of an underlying immunological problem has been suggested as an explanation for CFS.
If an underlying immunological problem is present, PCF and CFS patients might have an altered response to vaccination.
Aim Therefore, the aim of this study is to compare the humoral and cellular immune responses upon vaccination, using seasonal influenza vaccination as a model of a vaccination, in PCF and CFS patients, non-fatigued cancer survivors, and healthy controls.
Research questions
1. Is the humoral and/or cellular immune response after influenza vaccination different between fatigued patients (PCF and CFS) and non-fatigued individuals?
2. Is the humoral and/or cellular immune response after influenza vaccination different between PCF and CFS patients? Design The immune responses upon influenza vaccination will be assessed in 20 PCF patients and in 20 CFS patients. As a control group for PCF patients, 20 non-fatigued cancer survivors will be included. Additionally, 20 healthy controls will participate in this study as a control group without a cancer history and without fatigue symptoms. These four groups will be age- and sex-matched.
At baseline, participants will complete the Checklist Individual Strength, a questionnaire about the current use of medicines, and a questionnaire about their vaccination history. All participants will be intramuscularly vaccinated with a single dose of the seasonal influenza vaccine. Peripheral blood mononuclear cells will be collected at baseline (day 1) and 7 days after vaccination (day 8), and serum will be collected at baseline and 21 days after vaccination (day 22). Half a year after vaccination, all participants will be contacted to check whether a possible infection by influenza had taken place in the meantime or not.
The humoral immune responses on influenza vaccination will measured at day 1 and day 22 in serum by the haemagglutination-inhibition antibody test. The cellular immune responses will be measured at day 1 and day 8 by T lymphocyte proliferation, activation, and cytokine secretion.
Relevance of this study To the best of our knowledge, we are the first to explore both the humoral and cellular immune responses after influenza vaccination in both PCF and CFS patients. By means of this study, we would like to improve the understanding of the underlying physiology of PCF and CFS.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Seasonal influenza vaccination
Seasonal influenza vaccination
single dose of influenza vaccination
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Seasonal influenza vaccination
single dose of influenza vaccination
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Severely fatigued (CIS-fatigue score ≥ 35) or non-fatigued (CIS-fatigue \< 27)
* Treated for a malignant, solid tumor
* Completion of treatment for cancer minimal 1 year ago
* Disease-free, as defined by the absence of somatic disease activity parameters
* Severe, persistent or continuously returning complaints of fatigue, which do not improve noteworthy after rest and which are not the consequence of continuous exertion
* The fatigue resulted into a substantial decrease in former levels of professional, social and/or personal functioning
* The complaints cannot be explained by a physical cause
* The complaints persist for at least 6 months
Exclusion Criteria
* Physical comorbidity that could explain the fatigue
* Treatment with anti-depressive drugs, anti-epileptic drugs, or benzodiazepines
* A known immune deficiency
* Treatment with corticosteroids during the last 2 weeks
* Symptoms of influenza
* Allergy for chicken protein
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Radboud University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
H.W.M. van Laarhoven, Md
Role: PRINCIPAL_INVESTIGATOR
University Medical Centre Nijmegen st Radboud
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Medical Centre Nijmegen st Radboud
Nijmegen, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UMCNONCO201009
Identifier Type: -
Identifier Source: org_study_id